Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* All subjects:~  • Female subjects must be of non-child bearing potential OR use an effective method of contraception and sexually active males must use a condom during intercourse while taking the drug and for 5 half-lives after stopping treatment~* Subjects with hepatic impairment:~  * Subjects must have either mild, moderate or severe hepatic impairment~Exclusion criteria:~* All subjects~  * Hepatic impairment due to non-liver disease~ * Use of other investigational drugs at time of enrollment~ * History of malignancy of any organ system~ * Donation or loss of 400 mL or more of blood or plasma within 8 weeks prior to initial dosing~ * Hemoglobin levels below 10.0 g/dL at screening or baseline~* Subjects with hepatic impairment:~  * Presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk~ * Treatment with any cytostatic drug, vasodilator, autonomic alpha blocker or B2 agonist~ * Any surgical or medical condition other than hepatic impairment which might significantly alter the distribution or excretion of drugs~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- RLX030: Group 1 mild hepatic impairment (Type: EXPERIMENTAL): Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030
- RLX030: Group 2 moderate hepatic impairment (Type: EXPERIMENTAL): Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030
- RLX030: Group 3 severe hepatic impairment (Type: EXPERIMENTAL): Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030
- RLX030: Group 4 - healthy volunteers (Type: ACTIVE_COMPARATOR): Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).